Free shipping on all U.S. orders over $250 · Local pickup available in Morgan Hill, CA
PureLab Performancepurelabperformance.com
Research compoundEndocrine Signaling ResearchIn stock

Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that activates the ghrelin receptor (GHS-R1a) and was described in 1998 as a selective growth hormone secretagogue. Research includes rat, swine and cell studies and one published phase 2 trial.

Evidence: limited · Animal and cell studies; one phase 2 human trial

At a glance

Class
Pentapeptide ghrelin receptor agonist
Developer
No active pharmaceutical developer identified
FDA status
Not FDA-approved
Human data
One phase 2, randomized, placebo-controlled trial (published 2014)
Animal / lab data
Rat pituitary cells; rats and swine; rat bone-growth and post-surgical gut-motility models

Where it’s been studied

123
  • 1PituitaryPrimary pituitary cells, rat; GH release in rats and swine (1998)
  • 2BoneSkeletal measures, rat (1999)
  • 3GutPost-surgical gastric-emptying model, rat (2012)

Mechanism studied

Established: ipamorelin releases growth hormone through the GHRP (ghrelin) receptor pathway, shown in rat pituitary cells and with receptor antagonist studies [1]. Established in animals: unlike GHRP-6 and GHRP-2, it did not significantly raise ACTH or cortisol in swine and did not change FSH, LH, prolactin or TSH, which is why it was called selective [1]. Proposed: in rats, its effect on stomach emptying was attributed to ghrelin receptor action on cholinergic nerves [3].

What the research shows

StudyModelReported resultSource
Ipamorelin as a selective GH secretagogue [1]Other animal
Rat primary pituitary cells; anesthetized rats; conscious swine
GH release EC50 1.3 nmol/L in rat pituitary cells (efficacy 85% of GHRP-6); in swine, no rise in ACTH or cortisol beyond GHRH.Peer-reviewed
Eur J Endocrinol 1998
Ipamorelin and longitudinal bone growth [2]Rat
Rats given ipamorelin; bone length and body weight measured
Researchers reported increased longitudinal bone growth in rats.Peer-reviewed
Growth Horm IGF Res 1999
Post-surgical gastric-emptying model [3]Rat
Rats after laparotomy with intestinal manipulation; isolated gastric fundus strips
Meal retained at 15 min fell from 78% (vehicle) to 52% with ipamorelin; nonsurgical controls 44%. Fundus contractility was restored ex vivo.Peer-reviewed
J Exp Pharmacol 2012
Phase 2 post-surgical trial [4]Human
Phase 2, adults, randomized, double-blind, placebo-controlled, multicenter (2014)
Primary endpoint: time to tolerance of a standardized solid meal. Published.Peer-reviewed
Int J Colorectal Dis 2014

Human trials are listed for research context only; outcomes are reported in the linked publications. Animal and lab results do not establish effects in humans.

Verified by third-party testing

CertificatePosted on the product page
TestingIndependent, third-party

Research-grade supply

PureLab supplies Ipamorelin for laboratory research. Lot-specific certificates of analysis are posted on the product page as they are issued.

View research-grade Ipamorelin

More in Endocrine Signaling Research

Sources

  1. Raun K et al. (1998) Source
  2. Johansen PB et al. (1999) Source
  3. Greenwood-Van Meerveld B et al. (2012) Source
  4. Beck DE et al. (2014). doi:10.1007/s00384-014-2030-8 Source
For research use only. Not for human or veterinary use. Not a drug, food or cosmetic, and not intended to diagnose, treat, cure or prevent any disease. This library summarizes published research for educational purposes. PureLab Performance Inc.